GlassScriptPhysician profile
Alana Cheplowitz
NPI 1437616265
$20,293.48
in general payments reported to CMS, 2019-2025
30 companies · $3,987 in 2025
The $3,987 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,349 · 2022: $1,648 · 2023: $2,627 · 2024: $8,682 · 2025: $3,987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,180 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,925 · Consulting Fee: $1,680 · Travel and Lodging: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,180.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,925.00 |
| Consulting Fee | $1,680.00 |
| Travel and Lodging | $1,511.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $9,827.33 | 2023-2025 | |
| Abbvie INC. | $3,060.43 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $961.28 | 2021 | |
| Lilly USA, LLC | $894.96 | 2021-2024 | Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $846.05 | 2021-2025 | Ajovy, Austedo Xr, Austedo |
| Lundbeck LLC | $818.95 | 2021-2025 | Vyepti |
| Amgen INC. | $626.62 | 2021-2024 | Aimovig |
| Upsher-Smith Laboratories LLC | $416.35 | 2021-2023 | |
| Impel Pharmaceuticals INC. | $302.48 | 2023 | Trudhesa |
| Merck Sharp & Dohme LLC | $295.36 | 2021-2023 | Belsomra |
| Neurocrine Biosciences, INC. | $253.86 | 2022-2024 | Ingrezza, Ongentys |
| Allergan, INC. | $200.93 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $198.79 | 2022 | |
| Impel Pharmaceuticals LLC | $193.58 | 2024-2025 | Trudhesa |
| Takeda Pharmaceuticals U.S.A., INC. | $176.31 | 2021-2024 | Trintellix |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $163.93 | 2021-2022 | |
| Bausch Health US, LLC | $160.08 | 2021-2022 | |
| Axsome Therapeutics, INC. | $146.20 | 2023-2025 | Symbravo, Auvelity |
| Idorsia Pharmaceuticals US INC | $111.65 | 2023-2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $101.30 | 2021-2024 | Nuedexta, Rexulti |
| Tonix Medicines, INC. | $99.81 | 2024-2025 | Zembrace Symtouch |
| Currax Pharmaceuticals LLC | $90.95 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $76.20 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $76.14 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $59.92 | 2021 | |
| Amneal Pharmaceuticals LLC | $51.63 | 2023 | Lyvispah |
| Novo Nordisk INC | $24.22 | 2023 | Wegovy |
| Janssen Pharmaceuticals, INC | $23.89 | 2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.96 | 2024 | Caplyta |
| Almatica Pharma LLC | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alana Cheplowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.